In vitro activity of tedizolid against 43 species of Nocardia species
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract The purpose of the present study was to evaluate the in vitro activity of tedizolid against several clinically significant species of Nocardia by comparing with that of linezolid. A total of 286 isolates of Nocardia species, including 236 clinical isolates recovered from patients in Japan and 50 strains (43 species) purchased from NITE Biological Resource Center, were studied. Antimicrobial susceptibility testing was performed using the broth microdilution method. For the 286 Nocardia isolates, the minimal inhibitory concentration (MIC)50 and MIC90 values of tedizolid were 0.25 and 0.5 μg/ml, and those of linezolid were 2 and 2 μg/ml, respectively. The distribution of the linezolid/tedizolid ratios (MICs of linezolid/MICs of tedizolid) showed that tedizolid had four- to eight-fold higher activity than linezolid in 96.1% (275/286) of Nocardia isolates. Both the tedizolid and linezolid MIC90 values for Nocardia brasiliensis were two-fold higher than those for the other Nocardia species. Both tedizolid and linezolid had low MIC values, 0.25–1 μg/ml and 0.5–4 μg/ml, respectively, even against nine isolates (five species) that were resistant to trimethoprim/sulfamethoxazole. One Nocardia sputorum isolate showed reduced susceptibility to tedizolid (4 μg/ml). Bioinformatics analysis suggests different resistance mechanisms than the oxazolidinone resistance seen in enterococci and staphylococci.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- In vitro activity of tedizolid against 43 species of Nocardia species
- Date Crossref
- 04/03/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fukushima Medical University Department of Clinical Laboratory Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Fukushima Medical University Hospital pays non établi dans la noticeÉtablissement de santé
-
Chiba University Medical Mycology Research Center pays non établi dans la noticeUniversité ou école supérieure
-
Chiba University Hospital pays non établi dans la noticeÉtablissement de santé
-
School of Health Sciences Department of Clinical Laboratory Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Testing Department pays non établi dans la noticeÉtablissement de santé
Department of Clinical Laboratory Medicine — Fukushima Medical University, Fukushima Medical University Hospital et Medical Mycology Research Center — Chiba University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.